医薬品リファレンス
Trilaciclib
Trilaciclib is a medicine in the class oncology.
- 薬効分類: Oncology
最終更新日 出典: US FDA label
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
要点
- 薬効分類
- Oncology
- 一般的な剤形
- 注射剤
- 一般的な規格
- 300 mg/20 ml
- 既知の相互作用
- 28 (重大: 12 · 中等度: 13 · 軽度: 3)
- 商品名
- 1
- 国・市場
- 1
作用のしくみ
Transient inhibitor of CDK 4 and 6; proliferation of hematopoietic stem and progenitor cells in bone marrow depends on CDK4/6 activity.
成人の通常用量（添付文書の要約）
Decrease chemotherapy-induced myelosuppression in ES-SCLC: 240 mg/m2 as a 30-minute intravenous infusion completed no more than 4 hours before chemotherapy on each chemotherapy day; interval between doses on sequential days not greater than 28 hours
妊娠と授乳
- 妊娠
- Unsafe Can cause fetal harm based on its mechanism (CDK4/6 inhibitor); no human or animal data. Pregnancy test before starting; contraception during treatment and for at least 3 weeks after the last dose.
- 授乳
- Unsafe No data on milk levels or infant effects. Because of possible serious infant reactions, do not breastfeed during treatment and for at least 3 weeks after the last dose.
報告されている副作用
- Fatigue
- Hypocalcemia
- Hypokalemia
- Hypophosphatemia
- Increased aspartate aminotransferase
- Headache
禁忌
- History of serious hypersensitivity reactions to trilaciclib, including anaphylaxis.
注意が必要な方
- Injection-site reactions including phlebitis and thrombophlebitis; monitor, and stop infusion and permanently discontinue for severe or life-threatening reactions.
- Acute hypersensitivity reactions including facial edema, urticaria and anaphylaxis; withhold for moderate, permanently discontinue for severe or life-threatening.
- Interstitial lung disease/pneumonitis; monitor for cough, dyspnea, hypoxia and permanently discontinue for recurrent symptomatic or severe/life-threatening cases.
妊娠中または授乳中であること、腎臓や肝臓の病気、アレルギー、ほかに使用しているすべての薬やサプリメントについて、薬剤師または医師にお伝えください。
主な相互作用 (28)
- Alogliptin-metformin + Trilaciclib Major
- Canagliflozin-metformin + Trilaciclib Major
- Cisplatin + Trilaciclib Major
- Dalfampridine + Trilaciclib Major
- Dapagliflozin-metformin + Trilaciclib Major
- Empagliflozin-metformin + Trilaciclib Major
- Glyburide-metformin + Trilaciclib Major
- Linagliptin-metformin + Trilaciclib Major
- Metformin + Trilaciclib Major
- Metformin-pioglitazone + Trilaciclib Major
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、Trilaciclibの完全なモノグラフ（用量、妊娠・授乳、副作用、警告、すべての相互作用）を表示できます。
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- How to give it
- Pharmacokinetics
- Patient counselling points
WebでPro+を14日間無料でお試し。カード登録不要。
同じ分類のほかの薬剤
よくある質問
What is Trilaciclib used for?
Trilaciclib is a medicine in the class oncology.
What side effects have been reported with Trilaciclib?
Fatigue, Hypocalcemia, Hypokalemia, Hypophosphatemia, Increased aspartate aminotransferase, Headache.
Can Trilaciclib be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm based on its mechanism (CDK4/6 inhibitor); no human or animal data. Pregnancy test before starting; contraception during treatment and for at least 3 weeks after the last dose. Breastfeeding: Unsafe. No data on milk levels or infant effects. Because of possible serious infant reactions, do not breastfeed during treatment and for at least 3 weeks after the last dose.
What does Trilaciclib interact with?
MediHelp lists 28 known interactions for Trilaciclib. Major: 12 · Moderate: 13 · Minor: 3. The most serious include Alogliptin-metformin, Canagliflozin-metformin, Cisplatin.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。
